The study evaluates the effects of Prazosin on agitation in adults with Alzheimer's disease. Two thirds of the participants will participate in the medication portion, while one third will participate in the placebo portion
Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD)
Prazosin for Disruptive Agitation in Alzheimer's Disease (PEACE-AD) is a Phase IIb multicenter, randomized, double-blind, placebo-controlled trial of 12-weeks treatment with the brain active alpha-1 adrenoreceptor (AR) antagonist prazosin for disruptive agitation in approximately 186 Alzheimer's disease (AD) residents in a long-term care (LTC) setting or living at home with full-time caregiving. Distruptive agitation defined as having one or more of the following behaviors nearly daily during the previous week and at least intermittently for four weeks prior to screening: a) irritability, b) physically and/or verbally aggressive behavior, c) physically resistive to necessary care, d) and/or pressured motor activity (e.g., pressured pacing). LTC is defined as assisted living or skilled nursing facility. Home dwelling participants require full-time caregiving defined as having continuous daily caregiving and a Study Partner who will assist in providing protocol specific information to the study team. A previous single site pilot study addressing disruptive agitation in 22 predominantly LTC-residing AD participants demonstrated efficacy of prazosin on all three primary outcome measures.1 The current multicenter study is funded by the National Institute on Aging (NIA), and coordinated through the NIA-funded Alzheimer's Disease Cooperative Study (ADCS).
Alzheimer's Disease Disruptive Behavior Dementia Agitation PEACE-AD Alzheimer Disease Psychomotor Agitation Problem Behavior Prazosin
You can join if…
- Males and females with probable or possible AD by NINCDS-ADRDA criteria utilizing medical history; medical records review; and documented physical, neurological, and other examinations and laboratory tests. At Screening, physical, neurological and other examinations; and laboratory tests will be performed as possible and tolerated by the agitated participants. Brain imaging is not a requirement.
- Participants must reside in either a participating LTC or at home with full-time caregiving.
- Participants must have disruptive agitation significant enough to disrupt caregiving and, in the opinion of the Site Principal Investigator, to justify further treatment. Disruptive agitation, defined as having any combination of the following target behaviors, a) irritability, b) physically and/or verbally aggressive behavior, c) physically resistive to necessary care, and/or d) pressured motor activity (e.g., pressured pacing), must have occurred nearly daily during the previous week and at least intermittently for 4 weeks prior to screening, documented on the Behavioral Inclusion Criteria Checklist at Screening. Target behaviors may be any combination of the listed domains as long as they meet the above-described criteria for frequency and severity.
- Psychotropic medication, if used, should be stable for at least 2 weeks prior to randomization.
- If taking cholinesterase inhibitor and/or memantine, must be on stable dose(s) for 3 months prior to randomization.
- During the week before randomization, the above-described behaviors must be rated as of at least "moderate" severity. These behaviors must be problematic in that they cause participant and caregiver distress and/or interfere with essential care or disrupt their living environment.
You CAN'T join if...
- History of schizophrenia, schizoaffective disorder, or bipolar disorder according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM).
- Other neurodegenerative diseases, including Parkinson's disease and Huntington's disease, or cerebral tumor.
- Dementia other than probable or possible AD per NINCDS-ADRDA criteria, such as human immunodeficiency virus (HIV) dementia, Creutzfeldt-Jakob disease, frontotemporal dementia, multiple cerebral infarctions, or normal pressure hydrocephalus.
- Current treatment for seizure disorder. (Note: anticonvulsants prescribed for disruptive agitation are acceptable).
- Abnormal laboratory values with clinical significance in the opinion of the site Principal Investigator.
- Current unstable medical illness including delirium, worsening congestive heart failure, unstable angina, recent myocardial infarction (within the past 3 months), acute infectious disease, severe renal or hepatic failure, severe respiratory disease, metastatic cancer, or other conditions that, in the Site Principal Investigator's opinion, could interfere with the analyses of safety and efficacy in this study.
- Bedbound; participants may be ambulatory or use a wheelchair.
- Absence of any comprehensible language.
- Participation in another clinical trial for an investigational agent and took at least one dose of study drug (unless unblinded to placebo) within 12 weeks prior to screening. (The end of a previous investigational trial is defined as the date of the last dose of an investigational agent).
- . Preexisting recurrent hypotension (systolic blood pressure [BP] <110).
- . Preexisting orthostatic hypotension (>20 mmHg drop in systolic BP following 2 minutes of standing posture [or sitting if unable to stand], accompanied by dizziness, lightheadedness, or syncope).
- . A 2-week washout is required prior to BL for the following exclusionary medications: prazosin or other alpha-1 blocker, sildenafil, vardenafil, tadalafil, and avanafil.
- . Women of childbearing potential (must be at least 2 years post-menopausal or surgically sterile for inclusion).
- . The participant may not be an immediate family member of personnel directly affiliated with this study, the study site or study funding agency. Immediate family member is defined as a spouse, parent, child, or sibling, any of whom may be related by blood, adoption, or marriage.
- . Participants whom the Site Principal Investigator deems to be otherwise unsuitable for participation.
- University of California, San Diego (UCSD)
accepting new patients
San Diego California 92093 United States
- University of California Los Angeles
accepting new patients
Los Angeles California 90095 United States
Lead Scientist at UCSD
- Steven Huege, MD
Clinical Professor, Psychiatry. Authored (or co-authored) 7 research publications. Research interests: Medical Simulation · Geriatric Mental Health · Alzheimer's Disease · Interprofessional care and curriculum design · Geriatric psychiatry education.
- accepting new patients
- Start Date
- Completion Date
- Alzheimer's Disease Cooperative Study (ADCS)
- Phase 2
- Study Type
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.